RxDoctor Payments Data

Ronan Monsef, DO

Family Medicine · Farmingdale, NYNPI 1528132594

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 73 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • AbbVie$285
  • Amarin Pharma, Inc.$214
  • Icotec Medical Inc.$171
  • Hikma Pharmaceuticals USA$120
  • AstraZeneca$80
  • plus $225 from 8 others

What the payments were for

  • Food & beverage$1,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$127,213
Medicare patients
145
Services billed
1,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$36,516
JardianceEmpagliflozin16$26,255
MounjaroTirzepatide25$25,390
XareltoRivaroxaban11$17,373
EliquisApixaban13$15,465
SynthroidLevothyroxine Sodium79$7,375
Olmesartan Medoxomil115$2,317
Metoprolol Succinate121$1,578
Atorvastatin Calcium201$1,393
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid14$1,185
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$1,083
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,047
Albuterol Sulfate HfaAlbuterol Sulfate22$925
Levothyroxine Sodium63$891
Valsartan35$883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$314$36,51631 claims
Boehringer IngelheimJardiance$15$26,25516 claims
PfizerEliquis$71$15,46513 claims
AbbVieSynthroid$285$7,37579 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Farmingdale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →